JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans von Fourie, Anne M., Cheng, Xiaoli, Chang, Leon, Greving, Carrie, Li, Xinyi, Knight, Beverly, Polidori, David, Patrick, Aaron, Bains, Trpta, Steele, Ruth, Allen, Samantha J., Patch, Raymond J., Sun, Chengzao, Somani, Sandeep, Bhandari, Ashok, Liu, David, Huie, Keith, Li, Shu, Rodriguez, Michael A., Xue, Xiaohua, Kannan, Arun, Kosoglou, Teddy, Sherlock, Jonathan P., Towne, Jennifer, Holland, M. Claire, Modi, Nishit B.

Volltext

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects von Kosoglou, Teddy, Reyderman, Larisa, Tiessen, Renger G., van Vliet, André A., Fales, Robert R., Keller, Robert, Yang, Bo, Cutler, David L.

Volltext

Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler von Kosoglou, Teddy, PharmD, Hubbell, James, PhD, Cutler, David L., MD, Johnson-Levonas, Amy O., PhD, Xu, Danlin, PhD, Kantesaria, Bhavna S., MS, Kim, Kenneth, MD, Miller, S. David, MD

Volltext

HPA Axis Effects of Mometasone Furoate/Formoterol (MF/F) Versus Fluticasone Propionate/Salmeterol (FP/S) Administered via Metered-Dose Inhaler (MDI von Kosoglou, Teddy, PharmD, Hubbell, James, PhD, Xuan, Fengjuan, PhD, Cutler, David, MD, Johnson-Levonas, Amy, PhD, Xu, Danlin, PhD, Kantesaria, Bhavna, MS, Kim, Kenneth, MD, Miller, S. David, MD

Volltext

Once-Daily Evening Dosing of Mometasone Furoate Administered via a Dry Powder Inhaler Does Not Adversely Affect the Hypothalamic-Pituitary-Adrenal Axis von KOSOGLOU, Teddy, CUTLER, David L, STAUDINGER, Heribert, HERRON, Jerry M

Volltext

Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial von Finberg, Robert W, Lanno, Riin, Anderson, David, Fleischhackl, Roman, van Duijnhoven, Wilbert, Kauffman, Robert S, Kosoglou, Teddy, Vingerhoets, Johan, Leopold, Lorant

Volltext

Mometasone Furoate Has Minimal Effects on the Hypothalamic-Pituitary-Adrenal Axis When Delivered at High Doses von Affrime, Melton B., Kosoglou, Teddy, Thonoor, C. Mohan, Flannery, Brian E., Herron, Jerry M.

Volltext

A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study von O’Neil, Brian, Ison, Michael G, Hallouin-Bernard, Marie Charlotte, Nilsson, Anna C, Torres, Antoni, Wilburn, John M, van Duijnhoven, Wilbert, Van Dromme, Ilse, Anderson, David, Deleu, Sofie, Kosoglou, Teddy, Vingerhoets, Johan, Rossenu, Stefaan, Leopold, Lorant

Volltext

Ezetimibe : A review of its metabolism, pharmacokinetics and drug interactions von KOSOGLOU, Teddy, STATKEVICH, Paul, JOHNSON-LEVONAS, Amy O, PAOLINI, John F, BERGMAN, Arthur J, ALTON, Kevin B

Volltext

Mometasone furoate nasal spray : A review of safety and systemic effects von ZITT, Myron, KOSOGLOU, Teddy, HUBBELL, James

Volltext

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects von Bergman, Arthur J., Burke, Joanne, Larson, Patrick, Johnson-Levonas, Amy O., Reyderman, Larisa, Statkevich, Paul, Kosoglou, Teddy, Greenberg, Howard E., Kraft, Walter K., Frick, Glenn, Murphy, Gail, Gottesdiener, Keith, Paolini, John F.

Volltext

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment von Statkevich, Paul, Kosoglou, Teddy, Preston, Richard A., Kumar, Bharath, Xuan, Fengjuan, Trusley, Craig, Schiller, James E., Langdon, Ronald B., Cutler, David L.

Volltext

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar von Kosoglou, Teddy, Statkevich, Paul, Kumar, Bharath, Xuan, Fengjuan, Schiller, James E., Johnson-Levonas, Amy O., Young, Sophia, Cutler, David L.

Volltext

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease von Kosoglou, Teddy, Kraft, Walter K., Kumar, Bharath, Statkevich, Paul, Xuan, Fengjuan, Ma, Lei, Jennings, Lisa K., Schiller, James E., Langdon, Ronald B., Cutler, David L.

Volltext

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers von Anderson, Matt S., Kosoglou, Teddy, Statkevich, Paul, Li, Jing, Rotonda, Jennifer, Meehan, Alan G., Cutler, David L.

Volltext

ONCE-DAILY ADMINISTRATION OF MOMETASONE FUROATE DRY POWDER INHALER HAS NO SIGNIFICANT EFFECT ON CORTISOL CONCENTRATIONS IN SUBJECTS WITH MILD-TO-MODERATE ASTHMA von Kosoglou, Teddy, Cutler, David, Staudinger, Heribert

Volltext

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects von Chen, Xia, Kosoglou, Teddy, Statkevich, Paul, Kumar, Bharath, Li, Jing, Dockendorf, Marissa F, Wang, Guoqin, Lowe, Robert S, Jiang, Ji, Liu, Hongzhong, Wang, Zaiqi, Cutler, David L, Hu, Pei

Volltext

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin von Kosoglou, Teddy, Zhu, Yali, Xuan, Fengjuan, Black, Laura, Johnson-Levonas, Amy O., Martinho, Monika, Statkevich, Paul, Cutler, David L.

Volltext

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects von Kosoglou, Teddy, Reyderman, Larisa, Kasserra, Claudia, Jennings, Lisa K., Young, Sophia, Xuan, Fengjuan, Pei, Jinglan, Maxwell, Stephen E., Schiller, James, Meehan, Alan G., Cutler, David L.

Volltext

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin von Kosoglou, Teddy, Meyer, Ingo, Veltri, Enrico P., Statkevich, Paul, Yang, Bo, Zhu, Yali, Mellars, Lillian, Maxwell, Stephen E., Patrick, James E., Cutler, David L., Batra, Vijay K., Affrime, Melton B.

Volltext